Covidien Augments Endomechanical Biz With Stapler, Single-Incision Devices
This article was originally published in The Gray Sheet
Executive Summary
Covidien expects the recent slowdown in growth of its endomechanical business to dissipate with the launch of new products this year, the company said during its April 21 second-quarter earnings call
You may also be interested in...
Covidien Gains BIS Anesthesia Monitoring Technology In Aspect Medical Buy
Covidien is adding brain monitoring technology to its lineup through the $210 million acquisition of Aspect Medical Systems, announced Sept. 28
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.